Your browser doesn't support javascript.
loading
Defining cancer risk in dermatomyositis. Part I.
Madan, V; Chinoy, H; Griffiths, C E M; Cooper, R G.
Afiliación
  • Madan V; Dermatology Centre, Salford Royal Hospital NHS Foundation Trust, University of Manchester, Manchester, UK. vishalmadan@doctors.org.uk
Clin Exp Dermatol ; 34(4): 451-5, 2009 Jun.
Article en En | MEDLINE | ID: mdl-19522981
ABSTRACT
The idiopathic inflammatory myopathies (IIMs) comprise polymyositis, myositis overlapping with another connective tissue disease, dermatomyositis (DM) and inclusion-body myositis (IBM). IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle-specific enzymes, specific electromyographic abnormalities, and the presence of inflammatory cell infiltrates in skeletal muscle. Clinical, serological and histological criteria can be used to define individual IIM subtypes. In the first of this two-part review series, we examine the evidence for the existence of cancer-associated myositis (CAM), and in part 2, we discuss recent discoveries that provide insight into identification of patients with DM, who may be most at risk of developing CAM.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Dermatomiositis / Neoplasias Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2009 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Dermatomiositis / Neoplasias Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2009 Tipo del documento: Article